About CLTI
Technology
- Products
Clinical Evidence
U.S. Clinical Trial
Company
Contact
International

August 1 2017

LimFlow Announces Publication of Positive Results from Pilot Study of LimFlow Percutaneous Deep Vein Arterialization (pDVA) System

View the article.

LimFlow Announces First Patient Treated in U.S. Feasibility Study and Commencement of International Post-Market Study LimFlow Completes Enrollment In US Feasibility Study and Receives Breakthrough Device Status from FDA for Its Percutaneous Deep Vein Arterialization (pDVA) System

Related Posts

LimFlow System Demonstrates Excellent Sustained Amputation-Free Survival and Wound Healing at One Year in PROMISE I U.S. Study

Publication of Two-Year Outcomes for LimFlow System Shows Excellent Amputation-free Survival and Wound Healing in Patients With No-Option Chronic Limb-Threatening Ischemia

First Patient Enrolled in PROMISE II U.S. Pivotal Study of LimFlow System to Treat Chronic Limb-Threatening Ischemia

Recent Posts

LimFlow System Demonstrates Excellent Sustained Amputation-Free Survival and Wound Healing at One Year in PROMISE I U.S. Study
Publication of Two-Year Outcomes for LimFlow System Shows Excellent Amputation-free Survival and Wound Healing in Patients With No-Option Chronic Limb-Threatening Ischemia
First Patient Enrolled in PROMISE II U.S. Pivotal Study of LimFlow System to Treat Chronic Limb-Threatening Ischemia
LimFlow Announces Positive Six-month Data From PROMISE I U.S. Early Feasibility Study Demonstrating Excellent Amputation Free Survival and Wound Healing in No-option Patient Population
Limflow Receives FDA Approval for U.S. Pivotal Study of Minimally-Invasive Technology Designed to Prevent Amputations in Chronic Limb-Threatening Ischemia Patients

LimFlow, Inc.
2934 Scott Boulevard
Santa Clara, CA 95054 USA

info@limflow.com
+1 (888) 478-7705
+1 (408) 898-1459

CAUTION: Investigational device. Limited by Federal law to investigational use.

©2020 LimFlow SA | Site designed by The Deciding Factor, Inc.